Evaluation of carvedilol compatibility with lipid excipients for the development of lipid-based drug delivery systems – Abstract
Carvedilol (CARV) is a widely used non-selective β-blocker, which has shown low bioavailability after oral administration (20 %) due to its low water solubility and intense first-pass metabolism. Lipid-based drug delivery systems have been proposed to improve CARV oral bioavailability. An evaluation of drug–excipient compatibility is needed to clarify potential physical and chemical interactions between them and therefore guarantee a correct selection of excipients.